<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="./10_1101_2020_03_11_986836v1/results/search/disease/results.xml">
  <result pre="appealing potential of this drug for the treatment of the" exact="pneumonia" post="caused by SARS-CoV-2 infection. Moreover, molecular docking simulation suggested"/>
  <result pre="the treatment of COVID-19. 1. Introduction The outbreak of the" exact="pneumonia" post="named COVID-19 caused by the novel coronavirus SARS-CoV-2 (2019-nCoV)"/>
  <result pre="appealing potential drug candidate for the treatment of the novel" exact="pneumonia" post="caused by SARS-CoV-2 infection. Moreover, our molecular docking study"/>
  <result pre="Table 2). For example, chloroquine, an FDA-approved drug for treating" exact="malaria" post="[ 7], which was previously reported to exhibit micromolar"/>
  <result pre="top list for MERS-CoV, miltefosine, which was approved for treating" exact="leishmaniasis" post="[ 13], was previously identified to have anti-MERS-CoV activity"/>
  <result pre="[ 14]. Chlorpromazine and imatinib, which were used for treating" exact="schizophrenia" post="[ 15] and leukemia [ 16], respectively, were also"/>
  <result pre="imatinib, which were used for treating schizophrenia [ 15] and" exact="leukemia" post="[ 16], respectively, were also selected by our computational"/>
  <result pre="Figure 2A). In contrast, oseltamivir, zanamivir (drugs used for preventing" exact="influenza" post="virus infection) and baricitinib (JAK1/2 inhibitor, which was recommended"/>
  <result pre="such as human immunodeficiency virus (HIV) [ 20], foot and" exact="mouth disease" post="virus [ 21] and vesicular stomatitis virus (VSV) ["/>
  <result pre="20], foot and mouth disease virus [ 21] and vesicular" exact="stomatitis" post="virus (VSV) [ 22]. In addition, an in vivo"/>
  <result pre="MUSCLE [81]) of the N-NTDs among SARS-CoV-2, SARS-CoV, HCoV-OC43, mouse" exact="hepatitis" post="virus (MHV) and infectious bronchitis virus (IBV). The virus"/>
  <result pre="[ 81]) of the N-NTDs among SARS-CoV-2, SARS-CoV, HCoV-OC43, mouse" exact="hepatitis" post="virus (MHV) and infectious bronchitis virus (IBV). The virus"/>
  <result pre="also highly conserved among other viruses including SARS-CoV, HCoV-OC43, mouse" exact="hepatitis" post="virus (MHV) and infectious bronchitis virus (IBV) ( Figure"/>
  <result pre="PARP1 has been reported to interact with hemagglutinin (HA) of" exact="influenza" post="A virus (IAV) and promote its replication by triggering"/>
  <result pre="been suggested in previous studies to have neuroprotective effects in" exact="stroke" post="model and protect mice from necroptosis-associated liver injuries by"/>
  <result pre="(Acute Respiratory Distress Syndrome), COPD (Chronic Obstructive Pulmonary Disease) and" exact="asthma" post="[ 40, 46, 50, 51]. All these studies suggest"/>
  <result pre="are of high relevance to the treatment of the novel" exact="pneumonia" post="caused by SARS-CoV-2 infection, possibly via their roles in"/>
  <result pre="inhibitors into non-oncological diseases, including the aforementioned acute diseases (e.g.," exact="acute respiratory distress syndrome" post="(ARDS), stroke) [ 52] and chronic diseases (e.g., rheumatoid"/>
  <result pre="distress syndrome (ARDS), stroke) [ 52] and chronic diseases (e.g.," exact="rheumatoid arthritis" post="and vascular diseases) [ 52, 53]. All these evidences"/>
  <result pre="syndrome (ARDS), stroke) [ 52] and chronic diseases (e.g., rheumatoid" exact="arthritis" post="and vascular diseases) [ 52, 53]. All these evidences"/>
  <result pre="as a safe therapeutic agent to treat the current acute" exact="lung disease" post="caused by SARS-CoV-2 infection. In addition, our pharmacokinetic and"/>
  <result pre="2017 by National Medical Products Administration (NMPA) in China for" exact="cancer" post="treatment. The preliminary data from the Phase I clinical"/>
  <result pre=", Expression profile of immune response genes in patients with" exact="severe acute respiratory syndrome," post="BMC immunology 6 ( 1) ( 2005) 2. OpenUrl"/>
  <result pre="Neyts , M. Van Ranst , In vitro inhibition of" exact="severe acute respiratory syndrome" post="coronavirus by chloroquine, Biochemical and biophysical research communications 323"/>
  <result pre="V. Oldfield , K. Wellington , Gemcitabine, American journal of" exact="cancer" post="4 ( 5) ( 2005) 337– 344. OpenUrl 10."/>
  <result pre="mesylate capsules in the treatment of chronic myelogenous leukemia, Clinical" exact="cancer" post="research 8 ( 5) ( 2002) 935– 942. OpenUrl"/>
  <result pre="J. Stebbing , Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory disease," post="The lancet. 19. ↵ L. Velazquez-Salinas , A. Verdugo-Rodriguez"/>
  <result pre="Rodriguez , Increased virulence of an epidemic strain of vesicular" exact="stomatitis" post="virus is associated with interference of the innate response"/>
  <result pre="and MCP-1 in respiratory viral infection in acute exacerbations of" exact="chronic obstructive pulmonary disease" post=", Journal of immunology research 2017. 25. ↵ Y."/>
  <result pre=", R. M. Plenge , P. A. Nigrovic , The" exact="rheumatoid arthritis" post="risk variant CCR6DNP regulates CCR6 via PARP-1, PLoS genetics"/>
  <result pre="R. M. Plenge , P. A. Nigrovic , The rheumatoid" exact="arthritis" post="risk variant CCR6DNP regulates CCR6 via PARP-1, PLoS genetics"/>
  <result pre="M. Schwemmle , A. García-Sastre , Host-and strain-specific regulation of" exact="influenza" post="virus polymerase activity by interacting cellular proteins, MBio 2"/>
  <result pre="Ngo , H. Zhu , B. Hahm , PARP1 enhances" exact="influenza" post="A virus propagation by facilitating degradation of host type"/>
  <result pre="in DNA repair and inflammation: Pathological and therapeutic implications in" exact="cancer" post="and non-cancer diseases, Cells 9 ( 1) ( 2020)"/>
  <result pre="C. Conde , The role of poly (ADP-ribose) polymerase-1 in" exact="rheumatoid arthritis," post="Mediators of inflammation 2015. 54. ↵ D. Mendez ,"/>
  <result pre="83. K. Bhardwaj , How prepared are we to control" exact="severe acute respiratory syndrome" post="in future, Am. J. Virol 2 ( 2013) 8–"/>
  <result pre="a selective inhibitor of poly (ADP-ribose) polymerase, in experimental allergic" exact="encephalomyelitis" post="are associated with immunomodulation, Journal of pharmacology and experimental"/>
 </snippets>
</snippetsTree>
